# Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

> **NCT01980056** · PHASE1,PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 10 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Vosaroxin

## Key facts

- **NCT ID:** NCT01980056
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-25
- **Primary completion:** 2015-01-19
- **Final completion:** 2015-01-19
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01980056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01980056, "Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01980056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*